Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel in advanced gastric adenocarcinoma
NCT01497964Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2011
- Primary completion
- May 2013
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel ginsenoside liposome injection in gastric adenocarcinoma, sponsored by Sanofi. Primary endpoint: Objective Response Rate up to 2 years. Started Dec 2011; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT01497964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01497964.